<DOC>
	<DOCNO>NCT02018926</DOCNO>
	<brief_summary>Mocetinostat orally administer histone deacetylase ( HDAC ) inhibitor . Azacitidine hypomethylating agent ( HMA ) use treat MDS . In study , patient intermediate- high-risk MDS receive treatment mocetinostat azacitidine evaluate safety study treatment . Safety assessment include echocardiogram , electrocardiogram routine safety laboratory study ( hematology serum chemistry ) . In addition , clinical response treatment monitor use bone marrow aspirate biopsy , routine method .</brief_summary>
	<brief_title>Safety Study Mocetinostat Combination With Azacitidine Subjects With MDS</brief_title>
	<detailed_description>The study include multiple cohort patient . In first cohort , patient may previously receive treatment hypomethylating agent azacitidine . In late cohort , prior treatment class anti-cancer agent exclude . Later cohort include patient receive class agent , specifically azacitidine , first time .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Diagnosis intermediate highrisk ( IPSS criterion ) myelodysplastic syndrome . Cohort 1 : Any prior treatment , enrollment complete . Cohort 2 : Limited prior treatment MDS . Prior treatment include hypomethylating agent azacitidine decitabine , HDAC inhibitor . ECOG Performance Status 0 1 . Current history small , moderate large pericardial effusion , tamponade and/or pericarditis . Significant cardiac abnormality recent myocardial infarction , congestive heart failure â‰¥ Class 3 , symptomatic , uncontrolled atrial fibrillation , atrial flutter sinus tachycardia . Prolonged QT/QTc interval . Other active cancer exclude basal cell carcinoma cervical intraepithelial neoplasia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mocetinostat</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>HDAC</keyword>
	<keyword>HMA</keyword>
	<keyword>MDS</keyword>
</DOC>